The NZ Standards of Service Provision for Sarcoma patients were developed by the NZ Sarcoma working group and published by the Ministry of Health (MOH) in 2013. Although not formally enacted by the MOH we aimed to determine the impact of these published standards and referral pathways on disease-specific survival of patients with soft-tissue sarcoma in NZ. The Middlemore Musculoskeletal Tumour Unit database was searched. Patients referred for treatment in our centre with a diagnosis of soft tissue sarcoma in the five-year period before (n=115) and after (n=155) were included. We excluded patients with bone sarcomas and retroperitoneal soft tissue sarcomas. The rate of referral after inappropriate treatment reduced after implementation of the Standards (24% vs 12%, p=0.010). The number of patients referred with tumours larger than 50mm decreased (74.8% vs 72.3%, p=0.021) and fewer had metastases at diagnosis (11.3% vs 3.2%, p=0.017). Mortality was lower in the group after introduction of the Standards (45% vs 30%, p=0.017). The estimated disease-specific survival curve between the two groups shows a trend towards increased survival in the post-standards group, although not reaching statistical significance. Local recurrence rate and metastasis rate after definitive treatment were similar between the two groups. Patients had a shorter duration of symptoms before referral in the post-Standards group although this was not statistically significant. Since implementation of the Standards, patients have been referred more promptly, with fewer inappropriate treatments. The time to mortality curve indicates a trend towards improved disease-specific survival. We conclude that the pathway for investigation and referral for this condition has become clearer, supporting the ongoing use of the Sarcoma Standards, and that these should be formally implemented by the MOH.
STS are rare malignant tumours of mesenchymal origin giving a wide array of histological types and behaviour. Common sites of involvement include the extremities which are of most relevance to orthopaedic surgeons. Like almost all other malignancies, STS become more common with increasing age with median age of 65 years. All patients aged 65 and over with STS of the extremities referred to the NZ Tumour Registry at Middlemore Hospital between 1967 and 2010 were included in the study. Data collected include baseline demographics (age, sex), diagnosis, site, time of referral, definitive treatment, adjuvant therapy, surgical margins (if applicable), local recurrence, survival, and cause of death. Each patient was staged according to AJCC (1997, 5th edition) and Enneking's staging systems. Primary outcomes were measured in terms of 5-year survival alongside with cause of death. A total of 116 patients. 21 upper extremities, 95 lower extremities. Average age of 74 with a 1.2:1 female to male ratio. Stage 1 disease was uncommon, accounting for only 5 cases (4%). 3 patients died within 5 years (1 due to metastatic disease and 2 from non-sarcoma related disease). 2 patients were still alive in 2010 with 1 of them surviving >5yrs. Stage 2 disease was found in 41 patients (35%). Common histologies included malignant fibrous histiocytoma (MFH), liposarcomas, or leiomyosarcomas (LMS). 44% (n=18) had greater than 5-year survival. 20% (n=8) died within 5 years succumbing to metastatic disease. 11 were under 5-yr follow up. Stage 3 disease was found in 48 patients (41%). MFH was by far the most common diagnosis accounting for 63% of patients. 5-year survival 25% (n=12). 5-year mortality 56% (n=27) mainly from advanced disease and metastases. Rest (n=9) are still within 5-yr follow up. Distant metastases at presentation were seen in about 10% of all patients (12 cases) with the most common site of involvement being the lung. 9/13 died of metastatic disease within 5 yrs while others are still within the 5 yr follow up period. STS are most commonly observed in the elderly and prognosis depends on several factors. Management should ideally be carried in a specialised centre with early referral and combined multidisciplinary approach to optimise patient outcome.
We reviewed the charts of all patients (126) with a soft tissue tumour referred to the senior authors in 2006 and 2007. The information was stored in a prospective Tumour Registry Database. Where information was not available in records kept at our institution, the referring institution was contacted. There were 92 tertiary referrals and 34 GP referrals. The majority of the tertiary referrals came from orthopaedic surgeons (55), and general surgeons (28). The mean duration between referral and review was 16 days (0–215 days). There was a of 13 days wait for tertiary referral review. Tissue samples and histology reports accompanied 33 patients which had resulted from 35 invasive Pre Referral Procedures (PRP). This group suffered 21 complications affecting 18 patients. The remainder (91) were Pre Biopsy Referrals (PBR). Biospy was deemed necessary in 47 cases. The PBR group suffered 4 complications. Only one complication occurred to a patient with benign histology in each group. There was an extremely significant relationship between Pre Referral Procedures and suffering a complication (P<
0.0001). The relative risk of complication was 6.2 (C.I. 2.0–18.4) if an invasive procedure was performed prior to referral. There were 3 amputations (plus one recommended but refused by patient) in the PRP group and 1 amputation in the PBR group. This was not statistically significant. The median interval between referral and senior author review was 8 days for the PRP group and 10 days for the PBR group (P=0.2574). Sixty six percent of tertiary referrals were PBR (74% when including GP referrals). Biopsy of suspected appendicular Soft Tissue Sarcoma should be done by a tumour specialist or in prior consultation with one. There is virtually no delay to see an orthopaedic tumour specialist in New Zealand and achieving a tissue diagnosis does not expedite this.
The proximal humerus is the third most common site for primary sarcoma of bone. Since the 1970’s the treatment of primary bone sarcoma has changed from amputation to limb salvage. This has been due to advances in chemotherapy, imaging and surgical techniques. The literature has shown that the survival after limb salvage is similar to that of amputation. The optimum method of reconstruction of the shoulder remains controversial. The aim of our study was to review the cases of primary bone sarcoma of the proximal humerus treated at Middlemore Hospital. The New Zealand Bone Tumour Registry was searched for all lesions of the proximal humerus, with the diagnosis of chondrosarcoma, Ewing’s sarcoma or osteosarcoma. These records were reviewed for presentation status, biopsy, and type of reconstruct ion, chemotherapy, complications and recurrence. Outcomes measured in months of disease free survival and overall survival. The Bone Tumour Registry identified 29 patients who were treated at Middlemore Hospital with the primary diagnosis of Ewing’s sarcoma, chondrosarcoma or osteosarcoma of the proximal humerus. Results were available for 26 of the 29 patients (90% follow-up). Of these 29 patients six had chondrosarcoma, four Ewing’s sarcoma and 19 osteosarcoma. The patients with chondrosarcoma had an average age of 50 years. three patients were treated with endoprosthesis (mean survival 48 months) and one with vascularised fibula reconstruction (status 27 months ANED). Of the four patients with Ewing’s sarcoma, two had surgical reconstruction, one with intercalary allograft reconstruction (status 96 months ANED) and one with endoprosthesis (status 84 months ANED). The 19 patients with osteosarcoma had an average age 27 years, 15 patients were treated surgically. Three had endoprosthetic reconstruction (mean survival 29 months), two allograft prosthetic composite reconstruction (mean survival 23 months), three vascularised fibula reconstruction (mean survival 217 months), one total shoulder replacement and proximal humeral autograft (status 68 months ANED), one hemiarthroplasty (status 21 months DOD) and one proximal humeral allograft (status 31 months ANED). 4 patients were treated with primary amputation (mean survival 55.25 months). The mean overall survival for limb salvage surgery in our institution is 74 months compared to 55.25 months for amputation; this is consistent with the published literature. Function of a salvaged upper limb is superior to amputation. A salvaged limb is socially and emotionally more acceptable for patients than amputation. Limb salvage remains the priority in the treatment of primary bone tumours of the proximal humerus.
We reviewed and discussed the results of one hundred and fifty-five proximal femoral allografts for revision total hip replacement at an average of eleven years (range , five to twenty years).We looked at graft survivorship, functional results, radiographic assessment and complications. We concluded that this is an excellent technique for restoration of bone stock in the multiplied revised hip. To review the results of revision hip replacement with use of a proximal femoral allograft (PFA) to restore femoral bone stock. Between 1983 and 1998 a PFA – prosthetic composite was used to revise two hundred and twenty-seven hips in two hundred and ten patients. Of these two hundred and ten revisions involved an allograft longer than 8 cm. The average age of the patients at the time of revision was sixty-six years. The average number of previous total hip replacements was 2.2. Each patient was assigned a SF-12 score and a Short WOMAC Score. Radiographic assessment for trochanteric union, allograft-host union, component stability, graft fracture and resorption was performed. At an average of 11.2 years ( range, five to twenty years) after the revision, one hundred and eighty-five patients were alive, twenty-five patients had died and thirty were unavailable for follow-up. SF-12 and short WOMAC scores are still being calculated at the time of abstract submission. 4.4% of hips failed due to infection with 50% being successfully revised. Aseptic loosening of the construct occurred in 3.9% and 78% of these were revised at the time of follow-up. Nonunion of the allograft-host junction occurred in 4.8% and dislocation in 8.4%. Success was defined as a stable implant and no need for additional surgery at the time of follow-up. Success was noted in 84% of available cases. At an average of eleven years revision hip arthroplasties with a PFA are performing very well. This technique remains an excellent alternative when confronted with femoral bone loss in the revision hip setting.
This is a retrospective study of fifty nine hips in fourty nine patients with a previous total hip replacement for developmental dysplasia of the hip who underwent a revision arthroplasty of the hip. Fifty three patients were available for follow up. Radiographs and charts were reviewed and functional outcome scores were obtained in order to determine if a correlation existed between cup position and functional outcome and survivorship. Cup height was found to be a statistically significant predictor for functional outcome and cup survivorship. To determine if cup height, lateralization or angle are correlated with functional outcome or survivorship in revision total hip replacement (THR) in patients with a previous THR for developmental dysplasia of the hip (DDH). There is a paucity of literature correlating functional outcome with cup position in revision THR. Cup height was found to have a statistically significant (p<
0.05) correlation with Harris Hip, SF36, and WOMAC functional scores. High hip centers correlated with worse scores. In addition, patients with hip centers less than 3.5 cm above the radiographic tear drop had a statistically significant improvement in cup survivorship compared to those with higher hip centers. A retrospective investigation of forty-nine sequential patients (fifty-nine hips) previously diagnosed with DDH who underwent revision THR at our center between 1984 and 2000 was performed. Forty-three patients (fifty-three hips) were available for survivorship analysis and thirty-five patients (forty-five hips) were available for functional analysis. The mean follow up was one hundred and eighteen months (range 36–230). Three independent variables identified apriori as possible correlates were cup height, lateralization and angle as measured on the AP radiographs. Functional outcome measurement consisted of the Harris Hip, SF36 and WOMAC questionnaires. Linear regression analysis and Kaplan-Meier curves were used to determine if any of the variables correlated with functional outcome or survivorship. Restoration of hip center height to as close to the radiographic tear drop as possible improves functional outcome. Placement of the cup to within 3.5 cm of the tear drop improves cup survivorship.
Forty-six patients with an uncemented proximal tibial endoprosthesis were reviewed following resection of a proximal tibial tumor. The mean age was thirty-four years and the majority were male. The most common malignant diagnosis was osteosarcoma. Oncologic and functional analysis was performed on these cases. At latest follow-up thirty of the patients remain alive with no evidence of disease and eleven had died. The most common complication was deep infection (7/46). Only six patients had mechanical prosthesis related complications. At latest follow up the average TESS score was 76.3 and MSTS score 75.5 with an average extensor lag of 6.5o. To review the oncologic and functional results of a series of forty-six uncemented proximal tibia tumour replacements. A retrospective review of our prospectively collected database revealed forty-six patients with an uncemented proximal tibial replacement following tumour excision. The data was analysed with respect to patient demographics, operative and prosthetic complications. Oncologic diagnosis and results and functional results were also reviewed. The average age of the forty-six patients was thirty-four years (14–73) with thirty-three males and thirteen females. The most common diagnosis was osteosarcoma. There were four cases of benign GCT. At an average follow-up of 85.8 months (11–170), thirty were alive with no evidence of disease while eleven patients had died of their disease. Four patients were alive with evidence of disease at latest follow-up and one patient had died of unrelated causes. The most common operative complication was infection (9/46) with seven of these being deep infections requiring prosthesis removal, followed by mechanical problems including stem fracture (3/46) and bushing failure (3/46) also requiring operative intervention. Functional assessment revealed an average extensor lag of 6.5o with an average ROM of 83.6o, average TESS scores of 76.3 and MSTS 93 scores of 75.5. Large series of uncemented proximal tibial endoprostheses are uncommon in the literature. In our series there is a low rate of aseptic loosening at an average seven year follow-up, but this is offset by problems including infection and prosthetic fracture. Overall the functional and oncologic results remain satisfactory.
